𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of continuous mitomycin-C infusion in concomitant radiochemotherapy of primary inoperable advanced head and neck cancer

✍ Scribed by Hans Christiansen; Robert M. Hermann; Andrea Hille; Heinz Schmidberger; Alexios Martin²; Mirko Nitsche; Clemens F. Hess; Olivier Pradier

Publisher
Springer-Verlag
Year
2005
Tongue
English
Weight
200 KB
Volume
131
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Concomitant radiochemotherapy in primary
Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C
✍ Hans Christiansen; Robert M. Hermann; Andrea Hille; Elisabeth Weiss; Mirko Nitsc 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 534 KB

## Abstract ## Background. The purpose of this study was to evaluate the efficacy and toxicity of radiotherapy and concomitant 5‐fluorouracil (5‐FU) and mitomycin‐C infusion in inoperable head and neck cancer. ## Methods. Seventy‐six patients (86% men, 14% women), mean age 57 years, with primary

Simultaneous radiochemotherapy in the tr
Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single-institution study
✍ Giovanni Franchin; Carlo Gobitti; Emilio Minatel; Antonino de Paoli; Gianni Boz; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 2 views

Background. Patients with advanced, inoperable head and neck cancers have cure rates of approximately 10-15%. In these patients, concomitant chemoradiotherapy seems to improve local control and survival. 5-Fluorouracil(5-FU) administered by continuous infusion and cisplatin plus concomitant conventi

Neurotoxicity in a phase I trial of cont
Neurotoxicity in a phase I trial of continuous-infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer
✍ Gerald H. Clamon; Lynn Baatz; Henry T. Hoffman; David H. Hussey; Matthew Glascoc 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 569 KB

## Background: Both twice daily fractionated radiotherapy and concurrent cisplatin with once-daily radiotherapy have been shown to improve local disease control in patients with head and neck cancer. the objective of this phase i trial was to determine the maximum tolerated dose of cisplatin which

Concomitant cisplatin/5-FU infusion and
Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results
✍ Samuel G. Taylor IV; Anantha K. Murthy; Katherine L. Griem; Diane C. Recine; Kry 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 2 views

Background. The purpose of this study was to analyze long-term follow-up of a single institution's experience with a regimen of concomitant cisplatin/fluorouracil (5-FU) infusion and radiation given every other week. This analysis was stimulated by results of a randomized trial showing superiority f

A phase II study of cisplatin and contin
A phase II study of cisplatin and continuous infusion of vindesine in metastatic head and neck squamous cell cancer
✍ Eduardo Tellez-Bernal; Gonzalo Recondo; Thierry Guillot; Mohamed Benhamed; Chris 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 456 KB 👁 2 views

The chemotherapeutic treatment of recurrent and/or metastatic squamous cell carcinoma (SCC) of the head and neck (H & N) has a very dismal prognosis, with survival usually not exceeding 1 year. Reported objective response rates vary between 3% and 70%. This difference appears largely attributable to